TheracosBio
PrivateLast Round
Debt
Aug 22, 2023
Company Overview
TheracosBio is a biopharmaceutical company that develops and commercializes affordable therapeutic agents for prevalent diseases, with a primary focus on type 2 diabetes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, D2C Brands
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TheracosBio Comparables
Compare TheracosBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Johnson & Johnson | 77% | |
| Boehringer Ingelheim | 77% | |
| Eli Lilly and Company | 76% | |
TheracosBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Aug 22, 2023 | ||||
| VC Round | Jan 15, 2016 |
Key People
Founding team and executive leadership
TheracosBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HealthCare Royalty Partners | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2026
Monthly visitors increased 34% MoM.
- Jun 1, 2025
Monthly visitors grew 67% MoM, reaching 2,000.
TheracosBio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about TheracosBio's valuation, stock price, and market status.